pioglitazone has been researched along with Coronary Heart Disease in 19 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease (CHD)." | 9.20 | [Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease]. ( Borzykh, OA; Byelan, OV; Kaidashev, IP; Mamontova, TV, 2015) |
| " Thus, the aim of our study was to investigate the effect of pioglitazone on endothelial dysfunction, insulin sensitivity, and glucose control in newly detected type 2 diabetic patients with CAD." | 9.12 | Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. ( Sourij, H; Wascher, TC; Zweiker, R, 2006) |
| "To investigate the clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease (CHD)." | 5.20 | [Clinical effectiveness of pioglitazone in the combination treatment of patients with asthma concurrent with coronary heart disease]. ( Borzykh, OA; Byelan, OV; Kaidashev, IP; Mamontova, TV, 2015) |
| " Thus, the aim of our study was to investigate the effect of pioglitazone on endothelial dysfunction, insulin sensitivity, and glucose control in newly detected type 2 diabetic patients with CAD." | 5.12 | Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. ( Sourij, H; Wascher, TC; Zweiker, R, 2006) |
| "Pioglitazone reduces the composite of all-cause mortality, non-fatal myocardial infarction, and stroke in patients with type 2 diabetes who have a high risk of macrovascular events." | 5.11 | Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. ( Betteridge, J; Birkeland, K; Charbonnel, B; Dormandy, JA; Eckland, DJ; Erdmann, E; Golay, A; Heine, RJ; Korányi, L; Laakso, M; Lefèbvre, PJ; Massi-Benedetti, M; Mokán, M; Moules, IK; Murray, GD; Norkus, A; Pirags, V; Podar, T; Scheen, A; Scherbaum, W; Schernthaner, G; Schmitz, O; Skene, AM; Skrha, J; Smith, U; Standl, E; Tan, MH; Taton, J; Wilcox, RG; Wilhelmsen, L, 2005) |
| " High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate." | 4.84 | Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE. ( Robinson, JG, 2007) |
| " Pioglitazone, an antidiabetic agent that acts primarily by decreasing insulin resistance, improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis." | 4.82 | The metabolic basis of atherogenic dyslipidemia. ( Vinik, AI, 2005) |
| "To assess the risk of myocardial infarction (MI) and coronary revascularization (CR), in diabetic patients who began rosiglitazone, pioglitazone, metformin, or sulfonylureas." | 3.74 | Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. ( Koro, CE; Landon, J; Walker, AM, 2008) |
| "The treatment with pioglitazone in type 2 diabetic patients significantly reduced leptin." | 2.72 | A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. ( Fukui, T; Itoh, S; Katagiri, T; Kawamura, K; Konno, N; Kusuyama, T; Nishio, K; Sakurai, M; Shigemitsu, M, 2006) |
| "Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke." | 2.46 | [Evidences demonstrating the effects of anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive Study and PERISCOPE Study]. ( Kawamori, R, 2010) |
| "Pioglitazone was associated with reduced all-cause mortality [OR 0." | 2.44 | Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. ( Gensini, GF; Lamanna, C; Mannucci, E; Marchionni, N; Monami, M, 2008) |
| "Inflammation is known to have a pathogenic role in atherosclerosis and the genesis of acute coronary syndromes." | 2.43 | Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. ( Gil-Ortega, I; Kaski, JC; Marzoa-Rivas, R; Ríos-Vázquez, R, 2006) |
| "An asymptomatic patient with type 2 diabetes has a cardiovascular risk comparable to that of a patient without diabetes who has a history of a myocardial infarction." | 1.31 | Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease. ( Blumenthal, RS; Nass, CM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (78.95) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Christoph, M | 1 |
| Herold, J | 1 |
| Berg-Holldack, A | 1 |
| Rauwolf, T | 1 |
| Ziemssen, T | 1 |
| Schmeisser, A | 1 |
| Weinert, S | 1 |
| Ebner, B | 1 |
| Ibrahim, K | 1 |
| Strasser, RH | 1 |
| Braun-Dullaeus, RC | 1 |
| Byelan, OV | 1 |
| Borzykh, OA | 1 |
| Mamontova, TV | 1 |
| Kaidashev, IP | 1 |
| Ziyadeh, N | 1 |
| McAfee, AT | 2 |
| Koro, C | 2 |
| Landon, J | 2 |
| Arnold Chan, K | 1 |
| Kawamori, R | 1 |
| Császár, A | 1 |
| Takagi, T | 1 |
| Yamamuro, A | 1 |
| Tamita, K | 1 |
| Yamabe, K | 1 |
| Katayama, M | 1 |
| Mizoguchi, S | 1 |
| Ibuki, M | 1 |
| Tani, T | 1 |
| Tanabe, K | 1 |
| Nagai, K | 1 |
| Shiratori, K | 1 |
| Morioka, S | 1 |
| Yoshikawa, J | 1 |
| Yki-Järvinen, H | 1 |
| Dormandy, JA | 1 |
| Charbonnel, B | 1 |
| Eckland, DJ | 1 |
| Erdmann, E | 1 |
| Massi-Benedetti, M | 1 |
| Moules, IK | 1 |
| Skene, AM | 1 |
| Tan, MH | 1 |
| Lefèbvre, PJ | 1 |
| Murray, GD | 1 |
| Standl, E | 1 |
| Wilcox, RG | 1 |
| Wilhelmsen, L | 1 |
| Betteridge, J | 1 |
| Birkeland, K | 1 |
| Golay, A | 1 |
| Heine, RJ | 1 |
| Korányi, L | 1 |
| Laakso, M | 1 |
| Mokán, M | 1 |
| Norkus, A | 1 |
| Pirags, V | 1 |
| Podar, T | 1 |
| Scheen, A | 1 |
| Scherbaum, W | 1 |
| Schernthaner, G | 1 |
| Schmitz, O | 1 |
| Skrha, J | 1 |
| Smith, U | 1 |
| Taton, J | 1 |
| Marx, N | 1 |
| Wöhrle, J | 1 |
| Nusser, T | 1 |
| Walcher, D | 1 |
| Rinker, A | 1 |
| Hombach, V | 1 |
| Koenig, W | 1 |
| Höher, M | 1 |
| Nishio, K | 1 |
| Sakurai, M | 1 |
| Kusuyama, T | 1 |
| Shigemitsu, M | 1 |
| Fukui, T | 1 |
| Kawamura, K | 1 |
| Itoh, S | 1 |
| Konno, N | 1 |
| Katagiri, T | 1 |
| Vinik, AI | 1 |
| Sourij, H | 1 |
| Zweiker, R | 1 |
| Wascher, TC | 1 |
| Ríos-Vázquez, R | 1 |
| Marzoa-Rivas, R | 1 |
| Gil-Ortega, I | 1 |
| Kaski, JC | 1 |
| Robinson, JG | 1 |
| Werner, C | 1 |
| Kamani, CH | 1 |
| Gensch, C | 1 |
| Böhm, M | 1 |
| Laufs, U | 1 |
| Walker, AM | 2 |
| Koro, CE | 1 |
| Mannucci, E | 1 |
| Monami, M | 1 |
| Lamanna, C | 1 |
| Gensini, GF | 1 |
| Marchionni, N | 1 |
| Nass, CM | 1 |
| Blumenthal, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| A Prospective, Randomized, Parallel-group, Adaptive Design Phase IIb/III, Multicenter Study, to Assess the Efficacy of Polychemotherapy for Inducing Remission of Newly Diagnosed Type 2 Diabetes.[NCT04271189] | Phase 2/Phase 3 | 180 participants (Anticipated) | Interventional | 2020-09-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for pioglitazone and Coronary Heart Disease
| Article | Year |
|---|---|
[Evidences demonstrating the effects of anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive Study and PERISCOPE Study].
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Multi | 2010 |
[Anti-atherosclerotic effect of pioglitazone--the first evidence of the role of triglyceride/HDL ratio].
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Body F | 2011 |
The metabolic basis of atherogenic dyslipidemia.
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; D | 2005 |
Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Topics: Atherosclerosis; Blood Platelets; Coronary Disease; Diabetic Angiopathies; Endothelium, Vascular; Hu | 2006 |
Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.
Topics: Coronary Disease; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Peroxisome Prolife | 2007 |
Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.
Topics: Aged; Cause of Death; Coronary Disease; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycem | 2008 |
8 trials available for pioglitazone and Coronary Heart Disease
5 other studies available for pioglitazone and Coronary Heart Disease
| Article | Year |
|---|---|
The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Topics: Adult; Aged; Cohort Studies; Coronary Disease; Death, Sudden; Female; Follow-Up Studies; Heart Rate; | 2009 |
The PROactive study: some answers, many questions.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Pio | 2005 |
Studies of diabetes, thiazolidinediones, and coronary heart disease.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Hospitalization; Humans; Hypoglycemic Agents; Myocardia | 2007 |
Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.
Topics: Cohort Studies; Coronary Disease; Databases, Factual; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2008 |
Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Middle Age | 2000 |